NL0012661870

InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

JENA, Germany, March 13, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting…

4 hours ago